Evercore ISI lowered the firm’s price target on Baxter to $45 from $46 and keeps an Outperform rating on the shares in an earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter call volume above normal and directionally bullish
- Baxter participates in a conference call with JPMorgan
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Baxter initiated with a Neutral at Goldman Sachs
- Baxter: HDx therapy data show 25% lower mortality rate up to four years